Kempharm Fundamentals

KMPH -  USA Stock  

USD 8.88  0.06  0.67%

Kempharm fundamentals help investors to digest information that contributes to Kempharm's financial success or failures. It also enables traders to predict the movement of Kempharm Stock. This fundamental analysis module provides a way for investors to measures Kempharm's intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kempharm stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Search Fundamentals 

 
Refresh
Kempharm Selling General and Administrative Expense is most likely to increase significantly in the upcoming years. The last year's value of Selling General and Administrative Expense was reported at 7.92 Million. The current Weighted Average Shares is estimated to increase to about 4.3 M, while Consolidated Income is projected to decrease to (13.8 M).

Kempharm Cash and Equivalents Analysis

Kempharm's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Kempharm Cash and Equivalents

4.44 MillionShare
Cash 
 = 
Bank Deposits 
+  
Liquidities 
More About Cash and Equivalents | All Equity Analysis

Current Kempharm Cash and Equivalents

    
  75.92 M  
Most of Kempharm's fundamental indicators, such as Cash and Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kempharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Kempharm Cash and Equivalents Historical Pattern

Today, most investors in Kempharm Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kempharm's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash and equivalents growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Kempharm cash and equivalents as a starting point in their analysis.
 Kempharm Cash and Equivalents 
Share
      Timeline 
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Compare to competition

Kempharm Cash and Equivalents

Cash and Equivalents

4.44 MillionShare
Kempharm Cash and Equivalents is most likely to increase significantly in the upcoming years. The last year's value of Cash and Equivalents was reported at 4.32 Million
In accordance with the recently published financial statements, Kempharm has 75.92 M in Cash and Equivalents. This is 90.75% lower than that of the Healthcare sector and 83.02% lower than that of the Biotechnology industry. The cash and equivalents for all United States stocks is 97.19% higher than that of the company.

Kempharm Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kempharm's current stock value. Our valuation model uses many indicators to compare Kempharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kempharm competition to find correlations between indicators driving Kempharm's intrinsic value. More Info.
Kempharm is currently regarded as number one stock in shares owned by institutions category among related companies. It is considered the number one company in total debt category among related companies making up about  171,553  of Total Debt per Shares Owned by Institutions. . Kempharm Total Debt is most likely to increase significantly in the upcoming years. The last year's value of Total Debt was reported at 70.35 Million
Kempharm is considered the number one company in revenue category among related companies. Market size based on revenue of Biotechnology industry is now estimated at about 192.39 Million. Kempharm retains roughly 23.32 Million in revenue claiming about 12% of stocks in Biotechnology industry.

Kempharm Current Valuation Drivers

We derive many important indicators used in calculating different scores of Kempharm from analyzing Kempharm's financial statements. These drivers represent accounts that assess Kempharm's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kempharm's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Average Assets99 M64.11 M30.53 M14.07 M10.91 M11.19 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(10.85 M)(37.32 M)(50.8 M)(19.38 M)(7.74 M)(8.35 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(10.85 M)(37.32 M)(50.8 M)(19.38 M)(7.74 M)(8.35 M)
Earnings before Tax(16.53 M)(43.43 M)(56.59 M)(24.54 M)(12.79 M)(13.8 M)
Average Equity(9.91 M)(44.71 M)(81.28 M)(75.36 M)(65.07 M)(70.21 M)
Enterprise Value112.15 M142.95 M135.37 M85.21 M114.02 M118.94 M
Free Cash Flow(30.41 M)(33.28 M)(54.22 M)(23.76 M)(1.97 M)(2.13 M)
Invested Capital152.37 M122.46 M77.67 M81.05 M69.7 M76.98 M
Invested Capital Average147.93 M137.1 M92.2 M76.47 M19.55 M20.07 M
Market Capitalization43.21 M59.36 M47.09 M12.6 M50.78 M61.81 M
Tangible Asset Value84.89 M52.46 M26.75 M10.51 M11.21 M11.5 M
Working Capital67.72 M34.39 M11.72 M1.54 M846 K868.26 K

Kempharm Institutional Holders

Institutional Holdings refers to the ownership stake in Kempharm that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kempharm's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kempharm's value.
Security TypeSharesValue
Blackrock IncCommon SharesM25.2 M
Vanguard Group IncCommon Shares1.2 M15.5 M
Group One Trading LpCall Options806.6 K10.3 M
Hudson Bay Capital Management LpCommon Shares723.1 K9.3 M
Sabby Management LlcPut Options7.1 K9.1 M
State Street CorpCommon Shares493.8 K6.3 M
Geode Capital Management LlcCommon Shares472.9 K6.1 M
Boothbay Fund Management LlcCommon Shares441.4 K5.7 M
Susquehanna International Group LlpCommon Shares359.1 K4.6 M

Kempharm Fundamentals

About Kempharm Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kempharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kempharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kempharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2021
Revenues13.3 M14.6 M
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kempharm without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamental Analysis Now

   

Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Kempharm Piotroski F Score and Kempharm Altman Z Score analysis. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.